Isleworth (NASDAQ:ISLE) announced this afternoon that it will not complete a business combination by its initial deadline of September 1, and will instead redeem all shares.
The SPAC will cease all operations on August 29, and shareholders are expected to receive shortly thereafter $10.01 per share. As a result of the liquidation, Isleworth has also cancelled its special meeting of shareholders to extend its deadline that was previously scheduled for tomorrow, August 26.
The move comes several weeks after the SPAC mutually terminated its combination agreement with biopharmaceutical company Cytovia on June 30. Although Isleworth kept the details on the termination to a minimum, it is likely the parties decided to terminate for the same reason a number of other SPACs recently have, which pertains to the headwinds in the SPAC market as well as volatility within the general market. The termination was effective immediately, but Isleworth stated at that time that it was, “currently assessing whether it should extend its life”.
Isleworth Healthcare, which priced an upsized $180 million IPO last year in February 2021, intended to find a revenue generating US healthcare company with direct-to-patient initiatives.
The healthcare-focused SPAC marks the 19th SPAC liquidation in 2022, and the 6th in August thus far. Isleworth was led by Chairman Allen Weiss and CEO Robert Whitehead alongside CFO and EVP Dan Halvorson. The SPAC initially announced its $367 million combination with Cytovia earlier this year on April 27.
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...
In June 2025, the SPAC market was marked by a notable rise in meeting delays, with adjournments and postponements playing a central role in extension activity, as sponsors navigated a more cautious market environment. Still, several SPACs secured shareholder approvals, and seven business combinations were completed during the month. At the same time, IPO issuance...
An In-Depth Look at SPAC Activity Through the Second Quarter & First Half 2025 Below is a summary of the first half of 2025 SPAC market. If you’d like a pdf copy, you can access the link HERE. Q2 kicked off in chaos. President Trump’s shifting and often contradictory tariff announcements sent markets reeling, driving...
At the SPAC of Dawn The market is set to be showered with new SPACs today as three more SPACs priced their IPOs overnight, bringing 2025’s total to 66, already surpassing the full-year total of 2024. After hours, Ribbon (NASDAQ:RIBB) also added a new SPAC deal to June’s tally just under the wire, bringing the...
NMP Acquisition Corp. (NASDAQ:NMPAU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “NMPAU”, Tuesday, July 1, 2025. The new SPAC plans to combine with a target company that has a resilient business model with potential to scale up revenue. NMP’s management...